Cancer name Multiple Myeloma
Cancer Type MM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment MiR-29b
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature MAP2K4
Official Symbol MAP2K4
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Additionally, we found reduction of both pIKBa and pP65 indicating downregulation of NF-kB signaling. Furthermore, miR-29b antagonized the STAT3 phosphorilation/activation and reduced the expression of MAP2K4 and JUN. Interestingly, upregulation of the anti-inflammatory protein suppressor of cytokine signalling 1 (SOCS1)was detected. This is consistent with previous findings by our group where transfection of miR-29b induced SOCS1 promoter demetylation in MM cells.Moreover,we found a reduced expressionof MCL1, a validated molecular target of miR-29b, whose downregulation has been recently linked with reduced inflammation in lung infections.
PMID 29158557
Title MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells